Brown Capital Management LLC Sells 254,648 Shares of CryoPort, Inc. $CYRX

Brown Capital Management LLC reduced its stake in CryoPort, Inc. by 6.3% in Q2, selling 254,648 shares. Analysts have set new price targets, with UBS Group and BTIG Research giving 'buy' ratings. CryoPort's stock opened at $9.88, with a market cap of $494.69 million. The company reported Q3 earnings of ($0.18) per share, beating estimates. CryoPort provides temperature-controlled supply chain solutions in various markets.

CryoPort FY2025 EPS Forecast Reduced by Leerink Partnrs

CryoPort, Inc. (NASDAQ:CYRX) has had its FY2025 earnings estimates lowered by Leerink Partners, with analyst P. Souda projecting a loss of ($0.86) per share, down from ($0.84). The consensus estimate for the company's full-year earnings is ($0.99) per share. Despite the downgrade, Leerink maintains a "Strong-Buy" rating on the stock. Other analysts have also adjusted their ratings and price targets, with an average rating of "Moderate Buy" and a consensus price target of $12.83. CryoPort's stock opened at $8.33, with a market cap of $417.06 million.

Cryoport, Inc. SEC 10-Q Report

Cryoport, Inc. has released its Q3 2024 Form 10-Q report, showcasing a 15.4% increase in total revenue to $44.2 million, driven by strong demand in Life Sciences Services and Products. Gross margin improved to 48.2%, while net loss attributable to common stockholders rose to $(8.9) million. The company supported 745 clinical trials globally, with significant growth in BioLogistics Solutions and demand for cryogenic equipment, particularly in EMEA and APAC regions. Future outlook suggests regenerative medicine therapies will be key revenue drivers.

Cryoport | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 44.23 M

CryoPort Inc’s Earnings Call: Growth and Challenges

CryoPort Inc's recent earnings call highlighted strong growth in Life Sciences Services and Products, with a 36% year-over-year increase in revenue from commercial cell and gene therapy. The company is expanding its offerings and has launched new vapor shippers while enhancing its global supply chain. Despite a revised revenue guidance of $170 million to $174 million for 2025, concerns arose over a sequential revenue decline and potential impacts from the government shutdown. Overall, CryoPort remains optimistic about its growth trajectory and strategic initiatives in the life sciences sector.